Company News

GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).

GOLDEN, Colo. — March 24, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study to evaluate the accuracy, workflow efficiency, safety, and acceptability of the tuberculin

Recent crises have shown that pandemics don’t simply strain health systems—they disrupt entire societies. Supply chains falter under global demand. Regulatory processes slow when speed is most vital. Health systems run short on qualified vaccinators. And affordability barriers delay access in the communities that need protection first.

GOLDEN, Colo. — November 4, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario,

GOLDEN, Colo. — October 21, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the 15th Annual Partnership Opportunities in Drug Delivery (PODD) conference, October 27-28, at Westin Copley Place in Boston, Massachusetts. The conference brings